Featured Publications
Sarecycline inhibits protein translation in Cutibacterium acnes 70S ribosome using a two-site mechanism
Lomakin I, Devarkar S, Patel S, Grada A, Bunick C. Sarecycline inhibits protein translation in Cutibacterium acnes 70S ribosome using a two-site mechanism. Nucleic Acids Research 2023, 51: 2915-2930. PMID: 36864821, PMCID: PMC10085706, DOI: 10.1093/nar/gkad103.Peer-Reviewed Original Research
2024
Mechanistic Basis for the Translation Inhibition of Cutibacterium acnes by Clindamycin
Lomakin I, Devarkar S, Grada A, Bunick C. Mechanistic Basis for the Translation Inhibition of Cutibacterium acnes by Clindamycin. Journal Of Investigative Dermatology 2024, 144: 2553-2561.e3. PMID: 39122144, DOI: 10.1016/j.jid.2024.07.013.Peer-Reviewed Original ResearchNetwork of water-mediated interactionsCutibacterium acnesPeptide bond formationNascent peptideWater-mediated interactionsTranslational inhibitionAntibiotic resistanceCryogenic electron microscopyA-resolutionMechanistic basesAntibiotic-based therapiesRRNAAminoacyl groupRibosomeAcne pathogenesisAcne therapyAntibiotic stewardshipClindamycinIncreased resistanceAcne vulgarisClinical targetsAcneAntibioticsPeptideTRNAClindamycin: A Comprehensive Status Report with Emphasis on Use in Dermatology.
Del Rosso J, Armillei M, Lomakin I, Grada A, Bunick C. Clindamycin: A Comprehensive Status Report with Emphasis on Use in Dermatology. The Journal Of Clinical And Aesthetic Dermatology 2024, 17: 29-40. PMID: 39148960, PMCID: PMC11324192.Peer-Reviewed Original ResearchAcne vulgarisTreatment of acne vulgarisApplication of clindamycinCutaneous bacterial infectionsAntibiotic treatment efficacyTopical clindamycinTopical agentsOral treatmentClindamycinSystemic agentsMultiple disease statesPharmacokinetic profileTreatment efficacyAntibiotic resistanceBacterial infectionsAntibiotic mechanismsTherapeutic valueRelevance to cliniciansDisease statesDermatologyLincosamide antibioticsAnti-inflammatoryGram-positiveAnaerobic bacteriaAcneScientific Rationale and Clinical Basis for Clindamycin Use in the Treatment of Dermatologic Disease
Armillei M, Lomakin I, Del Rosso J, Grada A, Bunick C. Scientific Rationale and Clinical Basis for Clindamycin Use in the Treatment of Dermatologic Disease. Antibiotics 2024, 13: 270. PMID: 38534705, PMCID: PMC10967556, DOI: 10.3390/antibiotics13030270.Peer-Reviewed Original ResearchSoft tissue infectionsTetracycline class antibioticsTreatment of dermatological diseasesMechanism of protein synthesis inhibitionClindamycin useStaphylococcal infectionsTissue infectionsClinical presentationAnti-inflammatory propertiesHidradenitis suppurativaEffective antibioticsTreatment optionsClindamycinClinical evidenceAcne vulgarisClinical basisProtein synthesis inhibitionDermatological indicationsAmeliorate inflammationAntibiotic resistanceDermatology practiceBacterial ribosomeDermatological diseasesClass antibioticsLesion formation